The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Running, not enrolling · Early Phase 1 · Has a placebo group

Conditions studied: Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response

In brief

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Key facts

Study ID
NCT07517068
Run by
University of California, Riverside
People needed
19
Starts
2025-09-17
Expected to finish
2026-12-15
Last updated by the study team
2026-04-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.